Seborrheic DermatitisPhase 2NCT06013371
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
A Phase 2 study testing PF-07038124 in people with Seborrheic Dermatitis and Papulopustular Rosacea, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.
Trial summary
This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai. The study will include 33-39 adult subjects with moderate-to-severe-Seborrheic dermatitis (SD) as well as 33-39 adult subjects with moderate-to-severe papulopustular rosacea (PPR). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Seborrheic Dermatitis, Papulopustular Rosacea
- What is being tested?
- PF-07038124
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 32 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Jul 2023to 18 Feb 2025
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female subjects ≥ 18 years of age at the time of signing the informed consent document.
- Subject is able to understand and voluntarily sign an informed consent document prior to participation in any study assessments or procedures.
- Subject is able to adhere to the study visit schedule and other protocol requirements.
- Diagnosis of SD and baseline IGA ≥ 3 with facial involvement
- OR
- Diagnosis of PPR, baseline IGA ≥ 3, and baseline inflammatory lesion count ≥ 12
Show all 13Show fewer
- Subject agrees to discontinue all treatments for SD and PPR from screening through study completion aside from the study drug
- Subject is judged to be in otherwise good overall health as judged by the investigator, based on medical history, physical examination, and laboratory testing. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).
- Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While on the study drug and for at least 90 days after the last application of the study drug, male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:
- Option 1: Any one of the following highly effective contraceptive methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy.
- OR
- Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]); PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
- The female subject's chosen form of contraception must be effective by the time the female subject is enrolled into the study.
Who cannot join
- The presence of any of the following will exclude a subject from enrollment:
- Subjects with other skin diseases that would interfere with the study assessment in the opinion of the investigator.
- Active bacterial, fungal, or viral skin infection within 2 weeks from study initiation.
- Subject has clinically significant (as determined by the investigator) renal, hepatic, hematologic, intestinal, endocrine, pulmonary, cardiovascular, neurological, psychiatric, immunologic, or other major uncontrolled diseases (e.g., malignancy, TB, thromboembolic events) that will affect the health of the subject during the study, or interfere with the interpretation of study results.
- Subject has previously received treatment with oral or topical PDE4 inhibitors.
- Current other topical treatments (e.g., topical corticosteroids, topical calcineurin inhibitors, topical JAK inhibitors, topical metronidazole, topical minocycline, topical ivermectin, topical azelaic acid, topical brimonidine, topical oxymetazalone, topical antihistamines, topical antibacterials) within 2 weeks of baseline.
Show all 13Show fewer
- Use of systemic non-biologic immunosuppressive medications, including, but not limited to, cyclosporine, systemic or intralesional corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus, oral JAK inhibitors within 4 weeks of study initiation.
- Use of systemic biologic immunosuppressive medications, including, but not limited to inhibitors of IL-17, IL-12/23, or IL-23, TNF inhibitors, dupilumab, and abatacept within 12 weeks of baseline.
- History of adverse systemic or allergic reactions to any component of the study drug.
- Current participation in any other study with a biologic investigational medication within 6 months of baseline, or non-biologic investigational medication within 12 weeks of baseline.
- Subject who is pregnant or breast feeding.
- SD or PPR Baseline IGA < 3; PPR inflammatory lesion count <12; SD with no facial involvement.
- Active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or positive HIV serology at the time of screening for subjects determined by the investigators to be at high-risk for this disease.
Trial locations and contacts
1 site in 1 country.
United States1 site
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
About this study
Official title: PDE4 Inhibition in the Treatment of Seborrheic Dermatitis and Papulopustular Rosacea With PF-07038124
This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai. The study will include 33-39 adult subjects with moderate-to-severe-Seborrheic dermatitis (SD) as well as 33-39 adult subjects with moderate-to-severe papulopustular rosacea (PPR). Subjects will be randomized 2:1 to receive study drug or placebo.
Enrolled subjects will apply topical PF-07038124 0.02% ointment once daily for 8 weeks. They will return for visits at weeks 4, 8, and 12 following study treatment initiation for repeat clinical assessments, medication reviews, tape-strip, blood and urine sample collections, and monitoring for adverse events.
Read the detailed description
After providing consent, all subjects will be assessed for study eligibility, which includes a review of the subjects past and current medical conditions, familial medical history and detailed review of past and current medications. Subjects will also undergo a review of past topical treatments/therapies for SD or PPR, and clinical assessments (SD: clinical SD score, IGA, Peak Pruritus Numerical Rating Scale [PP-NRS]; PPR: inflammatory lesion count, IGA, PP-NRS).
Subjects who meet inclusion criteria for eligibility may continue with the Baseline Visit (Week 0) or can be scheduled to return for the Baseline Visit within 28 days of the Screening Visit.
At Baseline/Week 0, subjects will undergo clinical assessments (SD: clinical SD Severity Score, IGA, PP-NRS; PPR: inflammatory lesion count, IGA, PP-NRS), review of concomitant medications, standardized clinical photography, and a Dermatology Life Quality index (DLQI) questionnaire. Subsequent clinical assessments including standardized clinical photography, and questionnaire completion will be performed at follow up visits at Week 4, Week 8, and Week 12. Skin tape-strip samples will be collected for mechanistic studies (described below) at baseline (lesional and non-lesional facial skin), Week 4 (lesional facial skin), Week 8 (lesional facial skin), and Week 12 (lesional facial skin). Additional blood samples will be collected and stored at baseline and at Week 8 (or early termination, whichever is first) for potential future mechanistic analyses.
- Conditions
- Seborrheic Dermatitis, Papulopustular Rosacea
- Being tested
- PF-07038124, Placebo Ointment
- Medical subject headings
- Dermatitis, Seborrheic, Rosacea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PF-07038124Drug
topical PDE4 inhibitor
Placebo OintmentDrug
matching placebo
| Study group | Role | What they receive |
|---|---|---|
| Sebderm PF-07038124 | Experimental | PF-07038124 0.02% ointment once daily for 8 weeks Receives: Drug: PF-07038124 |
| Sebderm Placebo | Placebo comparator | Placebo Ointment Receives: Drug: Placebo Ointment |
| Rosacea PF-07038124 | Experimental | PF-07038124 0.02% ointment once daily for 8 weeks Receives: Drug: PF-07038124 |
| Rosacea Placebo | Placebo comparator | Placebo Ointment Receives: Drug: Placebo Ointment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Subjects Reaching Investigator's Global Assessment (IGA) Success - Seborrheic Dermatitis (SD)
IGA success defined as: clear (0) or almost clear (1) and a reduction from baseline of ≥2 points score of 0 or 1 at 8 weeks. Full scale is scored from 0-4, higher score indicates more severe symptoms.
Clear (0) - Complete clear, no signs of SD
Almost Clear (1) - Only slight pink color or trace amounts of scaling
Mild (2) - Pink to red color, or slight
Moderate (3) - Distinct redness or clearly visible scaling
Severe (4) - Severe score in erythema or scaling
Measured: Baseline and Week 8
Percent Change in Lesion Count Papulopustular Rosacea (PPR)
Percent change from baseline in inflammation (papule/pustule) lesion count at 8 weeks
Measured: Baseline and Week 8
Secondary outcomes (12)
Change in SD Severity Score at 8 Weeks
Change from baseline in each component and overall SD score (composed of erythema, scaling, and pruritus components) at 8 weeks. Each component scored 0-4 (0 = absence, 1 = mild, 2 = moderate, 3 = significant, 4 = severe). Total score from 0-12. Higher score indicates more severe symptoms.
Measured: Baseline and 8 weeks
Number of Patients With Treatment Success Via IGA in PPR
IGA success is defined as clear (0) or almost clear (1),and a reduction from baseline of ≥2 points score of 0 or 1 at 8 weeks. Full scale is scored from 0-4, higher score indicates more severe symptoms.
Clear (0) - No inflammatory lesions present, no erythema
Almost Clear (1) - Very few, small papules/pustules, very mild erythema present
Mild (2) - Few small or large papules/pustules, moderate erythema
Moderate (3) - Several small or large papules/pustules, moderate erythema
Severe (4) - Numerous small and/or large papules/pustules, severe erythema
Measured: Baseline and 8 weeks
Percent Change in Clinical Erythema - PPR
Percent change from baseline in clinical erythema assessment at 8 weeks. Full scale is scored from 0-4, higher score indicates more severe symptoms.
Clear (0) -Clear skin with no signs of erythema
Almost Clear (1) - Almost clear; slight redness
Mild (2) - Mild erythema; definite redness
Moderate (3) - Moderate erythema; marked redness
Severe (4) - Severe erythema; fiery redness
Measured: Baseline and 8 weeks
Change in Patient Assessment of Erythema - PPR
Change from baseline in patient severity assessment of erythema at 8 weeks. Full scale is scored from 0-4, higher score indicates more severe symptoms.
Clear (0) - Clear of unwanted redness
Almost Clear (1) - Nearly clear of unwanted redness
Mild (2) - Somewhat more redness than I prefer
Moderate (3) - More redness than I prefer
Severe (4) - Completely unacceptable redness
Measured: Baseline and 8 weeks
Change in Lesion Count - PPR
Change from baseline and from 8 weeks in inflammatory (papule/pustule) lesion count at 12 weeks
Measured: Baseline, 8 weeks, 12 weeks
Change in IGA Score - SD and PPR
Change from baseline in IGA score at 8 weeks. Full scale is scored from 0-4, higher score indicates more severe symptoms.
SD Clear 0 Complete clear, no signs of SD Almost Clear 1 Only slight pink color or trace amounts of scaling Mild 2 Pink to red color, or slight Moderate 3 Distinct redness or clearly visible scaling Severe 4 Severe score in erythema or scaling Clear (0) - Complete clear, no signs of SD
PPR Clear 0 No inflammatory lesions present, no erythema Almost Clear 1 Very few, small papules/pustules, very mild erythema present Mild 2 Few small or large papules/pustules, moderate erythema Moderate 3 Several small or large papules/pustules, moderate erythema Severe 4 Numerous small and/or large papules/pustules, severe erythema
Measured: Baseline and 8 weeks
Percent Change in IGA Score - SD and PPR
Percent change from baseline in IGA score at 8 weeks. Full scale is scored from 0-4, higher score indicates more severe symptoms.
SD Clear 0 Complete clear, no signs of SD Almost Clear 1 Only slight pink color or trace amounts of scaling Mild 2 Pink to red color, or slight Moderate 3 Distinct redness or clearly visible scaling Severe 4 Severe score in erythema or scaling Clear (0) - Complete clear, no signs of SD
PPR Clear 0 No inflammatory lesions present, no erythema Almost Clear 1 Very few, small papules/pustules, very mild erythema present Mild 2 Few small or large papules/pustules, moderate erythema Moderate 3 Several small or large papules/pustules, moderate erythema Severe 4 Numerous small and/or large papules/pustules, severe erythema
Measured: Baseline and 8 weeks
Change in IGA Score - SD and PPR
Change from baseline in IGA at 12 weeks (i.e., 4 weeks after treatment cessation). Full scale is scored from 0-4, higher score indicates more severe symptoms.
SD Clear 0 Complete clear, no signs of SD Almost Clear 1 Only slight pink color or trace amounts of scaling Mild 2 Pink to red color, or slight Moderate 3 Distinct redness or clearly visible scaling Severe 4 Severe score in erythema or scaling Clear (0) - Complete clear, no signs of SD
PPR Clear 0 No inflammatory lesions present, no erythema Almost Clear 1 Very few, small papules/pustules, very mild erythema present Mild 2 Few small or large papules/pustules, moderate erythema Moderate 3 Several small or large papules/pustules, moderate erythema Severe 4 Numerous small and/or large papules/pustules, severe erythema
Measured: Baseline and Week 12
Change in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Week 8
Change from baseline in PP-NRS at 8 weeks On a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', patient rates their itch at the worst moment during the previous 24 hours. Higher score indicates more severe symptoms.
Measured: Baseline and Week 8
Number of Study Drug Related Adverse Events
Number of adverse events reported throughout the study that are deemed related to study drug.
Measured: 12 weeks
Frequency of Study Drug Related Adverse Events
The frequency at which adverse events that are deemed related to study drug are reported throughout the study.
Measured: 12 weeks
Severity of Adverse Events
Severity will be measured as a category (mild, Moderate, severe) according to CTCAE 5.0.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2023
- Study start19 Jul 2023
- Primary completion18 Feb 2025
- Study completion18 Feb 2025
Why it stopped: The study ended early after interim analysis.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Seborrheic DermatitisStudies of the same condition, open and under way.
- More trials run by Icahn School of Medicine at Mount SinaiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Subjects will be randomized 2:1 to either drug or placebo
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University, hospital or other
- Collaborators
- Pfizer
- Responsible party
- Principal investigator, Benjamin Ungar, Icahn School of Medicine at Mount Sinai
- Investigators
- Benjamin Ungar, MD, Principal investigator, Icahn School of Medicine at Mount Sinai
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06013371
- Sponsor's protocol ID
- STUDY-23-00464
- Status last verified
- Aug 2026
- First submitted
- 22 Aug 2023
- Last updated
- 14 Aug 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Data will be analyzed as aggregated data